Orange Book product · Brand (NDA)
EXELON
RIVASTIGMINE
At a glance
Jul 06, 2007
Approved
Brand (NDA)
Application
AB
TE code
None
Listed patents
Key dates
Approval
FDA approval date of this drug product.
Jul 06, 2007
19 yr 3 mo ago
Today
Pharmaceutical detail
Active ingredient
RIVASTIGMINE
Strength
9.5MG/24HR
Dosage form
FILM, EXTENDED RELEASE
Route
TRANSDERMAL
TE code
AB
Application
NDA 022083
Product number
002
Marketing status
RX
Reference listed drug (RLD)
Yes
Reference standard (RS)
Yes
Active-ingredient family
View full familyThis is a reference-listed drug (RLD) — the basis for generic (ANDA) applications. Other products sharing this ingredient are listed below.
- 2025RIVASTIGMINEGeneric (ANDA)
ANDA 215445 · YICHANG HUMANWELL
- 2019RIVASTIGMINEGeneric (ANDA)
ANDA 209063 · BRECKENRIDGE
- 2019RIVASTIGMINEGeneric (ANDA)
ANDA 206318 · ZYDUS PHARMS
- 2019RIVASTIGMINEGeneric (ANDA)
ANDA 207308 · AMNEAL PHARMS
- 2018RIVASTIGMINEGeneric (ANDA)
ANDA 205622 · MYLAN TECHNOLOGIES
- 2015RIVASTIGMINEGeneric (ANDA)
ANDA 204403 · ALVOGEN
Listed patents
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
